-transparent.png){kind=logo}
The development of monoclonal antibody-drug (anthracycline) conjugates (immunocytostatics) that has emerged during the last decade is briefly reviewed. Stress is layed on the various procedures that have been employed for the chemical attachment of daunorubicin (daunomycin) and doxorubicin (adriamycin) to spacers, high-molecular weight carrier molecules, and immunoglobulins. Anthracycline conjugates that have proved effective in mice with respect to the treatment of cancer are especially evaluated. Also a new method developed for the conjugation of rhodosaminyl anthracyclinones via a hydrolysable spacer, developed in our laboratories, is briefly communicated. Finally, import aspects for further developments of monoclonal antibody-drug conjugates are discussed.
P Hermentin, and
F R Seiler
May 2019,
The Lancet. Haematology,
P Hermentin, and
F R Seiler
January 1999,
Anticancer research,
P Hermentin, and
F R Seiler
January 2010,
Bioconjugate chemistry,
P Hermentin, and
F R Seiler
March 2021,
Cancers,
P Hermentin, and
F R Seiler
October 1999,
Current opinion in immunology,
P Hermentin, and
F R Seiler
May 2017,
Molecular cancer therapeutics,
P Hermentin, and
F R Seiler
March 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
P Hermentin, and
F R Seiler
January 1988,
Critical reviews in therapeutic drug carrier systems,
P Hermentin, and
F R Seiler
January 2020,
Recent patents on anti-cancer drug discovery,
P Hermentin, and
F R Seiler
May 1988,
Gan to kagaku ryoho. Cancer & chemotherapy,
